Illumina 과거 순이익 실적
과거 기준 점검 3/6
Illumina은 연평균 3.9%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 3.8% 감소했습니다. 매출은 연평균 0.7%의 비율로 증가했습니다. Illumina의 자기자본이익률은 31.9%이고 순이익률은 19.4%입니다.
핵심 정보
3.92%
순이익 성장률
3.53%
주당순이익(EPS) 성장률
| Life Sciences 산업 성장률 | 21.51% |
| 매출 성장률 | 0.70% |
| 자기자본이익률 | 31.88% |
| 순이익률 | 19.42% |
| 최근 순이익 업데이트 | 29 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
분석 기사 • May 11
We Think That There Are Issues Underlying Illumina's (NASDAQ:ILMN) Earnings
Unsurprisingly, Illumina, Inc.'s ( NASDAQ:ILMN ) stock price was strong on the back of its healthy earnings report. We...
내러티브 업데이트 • Apr 30
ILMN: Policy And Execution Risks Will Likely Outweigh Supportive Genome Consumable Pricing
Illumina's analyst-derived fair value has shifted modestly lower from $88.35 to $87.05 as analysts balance mixed target changes and view Roche's less aggressive genome pricing as a near term positive that supports assumptions for slightly stronger revenue growth and profit margins, along with a marginally lower future P/E. Analyst Commentary Street research around Illumina reflects a mix of views, with some analysts highlighting potential upside from competitive pricing developments and others trimming price targets in response to ongoing execution and valuation questions.
내러티브 업데이트 • Apr 15
ILMN: Future Returns Will Depend On Pricing Power And 2026 Tools Demand
Analysts have kept the fair value estimate for Illumina steady at $136.11 per share, with a mix of recent price target increases and trims reflecting updated views on growth, profitability, and competitive pricing after Roche's latest genome sequencing announcement. Analyst Commentary Recent research suggests that views on Illumina are mixed, with the Roche Axelios pricing helping sentiment while target changes reflect different views on execution risk and growth visibility.Seeking Alpha • Apr 10
Illumina: Competitive Threats Priced In
Summary Illumina fundamentals are improving, with FY26 expected to return to positive growth and enable operating leverage. Competition from Roche and others is a risk, but recent news appears priced in; shares have stabilized since the Roche Axelios reveal. FY26 guidance calls for 2% organic growth, EBIT margin expansion of 3% YoY, and further upside from the Somalogic acquisition. My DCF model supports a BUY rating with a $156 target price, implying 22% upside as margin expansion and NovaSeq X mix drive value. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 01
ILMN: Future Returns Will Depend On 2026 Tools Demand And Competitive Pricing
Illumina's analyst price target nudged up to about $136, as analysts point to slightly firmer revenue growth assumptions, a steady profit margin outlook, and supportive read-through from recent Street research, including Roche's less aggressive genome pricing. Analyst Commentary Street research around Illumina has turned more active, with several firms adjusting price targets and updating views on genomics demand and competitive risks.내러티브 업데이트 • Mar 18
ILMN: Future Returns Will Hinge On China Recovery And 2026 Tools Demand
Illumina's updated analyst price target sits slightly higher at about $136, with analysts citing firmer revenue and margin assumptions, a modestly higher discount rate, and supportive recent commentary on competitive pricing for whole genome sequencing consumables. Analyst Commentary Recent Street research on Illumina reflects a mix of optimism and caution, with several firms adjusting price targets and reassessing the setup for the next couple of years.내러티브 업데이트 • Mar 04
ILMN: Policy And Execution Risks Will Likely Limit Benefits From Supportive Consumables Pricing
Illumina's analyst price targets have seen a modest upward reset, with a slightly higher fair value estimate of $88.35. This is supported by Street research that highlights firmer competitive pricing in sequencing consumables and a range of recent target revisions tied to updated views on growth, margins, discount rates, and future P/E assumptions.내러티브 업데이트 • Feb 18
ILMN: Policy And Execution Risks Will Likely Restrain Tools Thesis Upside
Illumina's updated analyst price target has increased to $87.97 from $80.00. This reflects analysts' mixed but generally more constructive views as they adjust for revised revenue growth, profit margin and future P/E assumptions following a series of recent target changes across the Street.내러티브 업데이트 • Feb 03
ILMN: Future Returns Will Depend On China Access And 2026 Execution
Narrative Update: Illumina Analyst Target Shift Our Analyst Price Target for Illumina moves modestly higher by about $4 per share as analysts cite updated views on revenue growth, profit margins, and future P/E multiples following a series of recent price target increases across the Street. Analyst Commentary Bullish and cautious voices are both weighing in on Illumina, and most of the recent activity centers on refreshed views for 2026, broader life science tools demand, and where valuation might settle after recent share moves.내러티브 업데이트 • Jan 20
ILMN: Future Returns Will Depend On China Recovery And Execution Through 2026
Analysts have raised their implied fair value for Illumina by about $12 to approximately $132 per share, reflecting updated views on revenue growth, profit margins and future P/E multiples, supported by a series of recent price target increases across the Street. Analyst Commentary Recent research updates cluster around higher price targets and mixed views on how reliably Illumina can deliver against those expectations.내러티브 업데이트 • Jan 06
ILMN: China Export Restrictions Will Likely Cap Upside Despite Cost Efficiencies
Analysts have raised their price targets on Illumina to a range of roughly $100 to $195, citing recovering end markets, healthier procedure and CapEx trends into 2026, and cost efficiencies highlighted in recent quarterly results, even as they continue to flag limited visibility and ongoing challenges in China. Analyst Commentary Recent research updates present a mixed picture for Illumina, with higher price targets sitting alongside ongoing questions around visibility, execution, and regional headwinds.내러티브 업데이트 • Dec 14
ILMN: China Export Risks Will Likely Limit Upside Despite Recent Optimism
Analysts raised our implied fair value estimate for Illumina by 7 dollars to 80 dollars per share. This reflects higher revenue growth and profit margin expectations following better than anticipated quarterly results and a series of upward price target revisions across the Street, despite lingering visibility concerns.내러티브 업데이트 • Nov 30
ILMN: Future Performance Will Rely On China Market and Operational Execution
Analysts have modestly increased their price targets for Illumina, with the fair value estimate rising by $2.11 per share to $119.84. This reflects confidence in the company’s recent quarterly performance and operational improvements despite ongoing sector headwinds.내러티브 업데이트 • Nov 16
ILMN: Future Momentum Will Depend On China Recovery And Efficiency Gains
Analysts have modestly raised their price target on Illumina, increasing fair value estimates from approximately $113.58 to $117.74. This reflects improved revenue growth and operational efficiency, despite mixed business visibility and regional challenges.분석 기사 • Nov 09
Illumina, Inc. (NASDAQ:ILMN) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
The Illumina, Inc. ( NASDAQ:ILMN ) share price has done very well over the last month, posting an excellent gain of...내러티브 업데이트 • Nov 01
ILMN: Operational Progress Will Offset Ongoing China Exposure And Sector Uncertainties
Illumina's analyst price target has increased modestly, with the average rising from $111.95 to $113.58. Analysts cite stronger operational performance and revenue growth, even as the company faces ongoing sector and regional challenges.내러티브 업데이트 • Sep 04
Next-generation Sequencing Will Expand Clinical Capabilities Despite Risks
Illumina’s unchanged analyst price target reflects a balance between optimism for sector-leading EPS growth and resilience in consumables, and caution around persistent funding pressures, regulatory risks, and macroeconomic uncertainties, resulting in a maintained fair value of $111.95. Analyst Commentary Mixed quarterly performance prompted both positive and conservative price target adjustments, with solid earnings and guidance raises offset by ongoing academic funding pressures.분석 기사 • Aug 31
Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)
Key Insights Illumina's estimated fair value is US$107 based on 2 Stage Free Cash Flow to Equity Current share price of...분석 기사 • Aug 08
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues
NasdaqGS:ILMN 1 Year Share Price vs Fair Value Explore Illumina's Fair Values from the Community and select yours...분석 기사 • Aug 05
Illumina, Inc. Just Recorded A 76% EPS Beat: Here's What Analysts Are Forecasting Next
NasdaqGS:ILMN 1 Year Share Price vs Fair Value Explore Illumina's Fair Values from the Community and select yours...분석 기사 • Jul 09
Illumina, Inc.'s (NASDAQ:ILMN) Shareholders Might Be Looking For Exit
When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...분석 기사 • Jun 13
These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Mar 27
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
Summary The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing market is expected to grow by 14.90%-21.65% CAGR in the following ten years. Despite the losses that Illumina has incurred due to its GRAIL divestiture, the company will not continue to finance GRAIL in the upcoming years. Read the full article on Seeking AlphaSeeking Alpha • Mar 05
Illumina: Navigating Headwinds As China Bans Instruments And Roche Enters The NGS Race
Summary Illumina faces significant challenges from China's "unreliable entity list" and competition from Roche's new SBX technology, impacting its growth prospects. Despite a 37% stock decline since August, Illumina remains a leader in NGS with promising long-term growth, though the short-term outlook is cautious. Illumina's Q4 financials show improved gross margins and strong free cash flow, but geopolitical risks and modest growth temper optimism. Downgrade to "hold" as competitive and geopolitical risks are priced in, but Illumina's leadership and operational improvements warrant a balanced perspective. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Illumina And Grail In 2025? Grounds For Optimism, If Mistakes Aren't Repeated
Summary Illumina, Inc.'s acquisition of GRAIL, Inc. was disastrous and created all kinds of problems, but the company is refocusing on its profitable core gene sequencing business. ILMN's revenue growth has plateaued, but its high operating margins and strategic product refinements make it a stable investment. Grail, while promising, needs more time to establish itself in the market and currently faces significant financial challenges. Both Illumina and Grail are rated as 'hold' due to past missteps and the need for a stable, trouble-free year ahead. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
Illumina: Q3 Confirms Improving Fundamentals
Summary Illumina is the leader in the undisputed Next Generation Sequencing market. Grail divestment is behind, enabling a margin expansion and fueling a more robust cash flow generation. The stock was down after hours, as much good news has been priced in the recent rally. However, as revenue growth should accelerate starting in 2025, there is still room for further upside. My DCF model indicates further upside, so I keep my BUY rating. Read the full article on Seeking Alpha매출 및 비용 세부 내역
매출 및 비용 세부 내역
Illumina가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 29 Mar 26 | 4,393 | 853 | 1,185 | 864 |
| 28 Dec 25 | 4,343 | 850 | 1,164 | 865 |
| 28 Sep 25 | 4,288 | 703 | 1,103 | 870 |
| 29 Jun 25 | 4,284 | 1,257 | 1,101 | 893 |
| 30 Mar 25 | 4,337 | -966 | 1,266 | 971 |
| 29 Dec 24 | 4,372 | -1,223 | 1,394 | 1,068 |
| 29 Sep 24 | 4,390 | -1,585 | 1,641 | 1,118 |
| 30 Jun 24 | 4,429 | -3,044 | 1,631 | 1,180 |
| 31 Mar 24 | 4,493 | -1,290 | 1,629 | 1,204 |
| 31 Dec 23 | 4,504 | -1,161 | 1,620 | 1,207 |
| 01 Oct 23 | 4,465 | -1,125 | 1,572 | 1,234 |
| 02 Jul 23 | 4,461 | -4,186 | 1,677 | 1,246 |
| 02 Apr 23 | 4,448 | -4,487 | 1,636 | 1,227 |
| 01 Jan 23 | 4,584 | -4,404 | 1,614 | 1,209 |
| 02 Oct 22 | 4,700 | -4,153 | 1,682 | 1,242 |
| 03 Jul 22 | 4,693 | -20 | 1,510 | 1,187 |
| 03 Apr 22 | 4,656 | 701 | 1,550 | 1,061 |
| 02 Jan 22 | 4,526 | 762 | 1,744 | 914 |
| 03 Oct 21 | 4,280 | 907 | 1,351 | 794 |
| 04 Jul 21 | 3,966 | 769 | 1,350 | 696 |
| 04 Apr 21 | 3,473 | 630 | 1,114 | 650 |
| 03 Jan 21 | 3,239 | 656 | 1,014 | 609 |
| 27 Sep 20 | 3,238 | 638 | 813 | 572 |
| 28 Jun 20 | 3,351 | 693 | 811 | 551 |
| 29 Mar 20 | 3,556 | 942 | 835 | 562 |
| 29 Dec 19 | 3,543 | 1,002 | 907 | 575 |
| 29 Sep 19 | 3,458 | 973 | 874 | 607 |
| 30 Jun 19 | 3,405 | 938 | 881 | 615 |
| 31 Mar 19 | 3,397 | 851 | 877 | 600 |
| 30 Dec 18 | 3,333 | 826 | 849 | 568 |
| 30 Sep 18 | 3,243 | 684 | 798 | 538 |
| 01 Jul 18 | 3,103 | 648 | 768 | 513 |
| 01 Apr 18 | 2,936 | 567 | 732 | 492 |
| 31 Dec 17 | 2,752 | 725 | 720 | 500 |
| 01 Oct 17 | 2,594 | 775 | 692 | 488 |
| 02 Jul 17 | 2,487 | 741 | 664 | 480 |
| 02 Apr 17 | 2,424 | 730 | 652 | 474 |
| 01 Jan 17 | 2,398 | 454 | 630 | 458 |
| 02 Oct 16 | 2,371 | 440 | 624 | 450 |
| 03 Jul 16 | 2,314 | 430 | 621 | 423 |
| 03 Apr 16 | 2,253 | 415 | 597 | 395 |
| 03 Jan 16 | 2,220 | 462 | 561 | 362 |
| 27 Sep 15 | 2,141 | 510 | 533 | 348 |
| 28 Jun 15 | 2,071 | 486 | 516 | 334 |
양질의 수익: ILMN는 $213.0M 규모의 큰 일회성 이익이 있어 29th March, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.
이익 마진 증가: ILMN는 과거에 흑자전환했습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: ILMN는 지난 5년 동안 흑자전환하며 연평균 3.9%의 수익 성장을 기록했습니다.
성장 가속화: ILMN는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.
수익 대 산업: ILMN는 지난해 흑자전환하여 지난 해 수익 성장률을 Life Sciences 업계(3.8%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: ILMN의 자본 수익률(31.9%)은 높음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/24 15:30 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/29 |
| 연간 수익 | 2025/12/28 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Illumina, Inc.는 44명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Rakesh Patel | Barclays |